Liver and Kidney Interactions in Health and Critical Illness

James D. Fortenberry MD, FCCM, FAAP
Associate Professor, Department of Pediatrics
Emory University School of Medicine
Director, Critical Care Medicine and ECMO
Children’s Healthcare of Atlanta at Egleston
The Liver and Kidney in Health

- Short list
- Vitamin D metabolism: 25,1-hydroxylation
- Hepatic regulation of renal function
  - Uncertain normal state
  - Hepatic osmoreceptors?
  - Enteral ingestion of protein: increased GFR
    - Liver-borne diuretic factor?

- Lang, Tschernko, Haussinger Exp Physiol 1992:77,663
The Liver and Kidney in Critical Illness

- Renal failure in the setting of liver failure
- Hepatorenal syndrome
- Liver transplant-associated interactions
Causes of Renal Failure in Patients with Liver Disease

- Prerenal
  - Volume depletion
  - Congestive heart failure
  - Nephrotic syndrome
  - Anaphylaxis
  - Anesthesia
- Renal
  - ATN
  - Toxic-drugs, solvents, heavy metals, heme
- Postrenal
  - Ureteral, bladder-outlet obstruction
- No specific cause: Hepatorenal Syndrome (HRS)
Hepatorenal Syndrome (HRS)

- Frerichs (1861) and Flint (1863): first noted association of liver disease and oliguria without renal histologic changes
- Hecker and Sherlock (Lancet 1956) describe HRS
- Still no definitive treatment

Hepatorenal Syndrome (HRS): Diagnostic Criteria

- **6 Major Criteria (Adult-no pediatric)**
  - Low GFR (SCr > 1.5 mg/dl or CrCl < 40 ml/min)
  - Absence of shock, ongoing bacterial infection, fluid losses, nephrotoxic drugs
  - No sustained improvement in renal function
  - Proteinuria < 500 mg/dl
  - No U/S evidence of obstructive uropathy or parenchymal renal disease

- **Additional Criteria**
  - Urine volume < 500 ml/day
  - Urine sodium < 10 mEq/L, serum Na < 130 mEq/L
  - Urine osmo > plasma osmo
Hepatorenal Syndrome (HRS): Types

- **Type 1**
  - Rapidly progressive renal failure
  - Doubling of creatinine
  - Precipitating factor frequently identified
- **Type 2**
  - Moderate, steady renal failure
  - Milder elevation of creatinine
  - May arise spontaneously
Hepatorenal Syndrome (HRS): Does It Exist in Children?

- Little data-short answer: yes
- HRS most often occurs with advanced liver disease
- Can occur with acute hepatic failure/FHF
- No specific criteria for HRS in children
- Estimated 5% incidence of HRS in children with chronic liver disease (vs. 10-15% in adults)
HRS: Mechanism

- **Hallmark:** Intense renal vasoconstriction
- Starts at an early time point and progresses with worsening liver disease
- Not well studied in humans
1. Peripheral (splanchnic) arterial vasodilation $\Rightarrow$ subsequent renal vasoconstriction
2. Stimulation of renal sympathetic nervous system
3. Cardiac dysfunction $\Rightarrow$ circulatory derangements and renal hypoperfusion
4. Cytokine/mediator action on renal circulation
Peripheral arterial vasodilation → subsequent renal vasoconstriction:

- ECV ↓ 2° to increased resistance through cirrhotic liver→increased splanchnic pooling
- Vasodilation of systemic and splanchnic circulation (cytokines)
- Activation of SNS, renin-angiotensin→ hyperdynamic circulation with ↓ SVR, ↑ CO,↓ MAP
- Hyperdynamic circulation→renal vasoconstriction
Stimulation of renal sympathetic nervous system:

- SNS tone increased with cirrhosis
- Increased intrahepatic pressure increases SNS = hepatorenal reflex?
- Increased arginine vasopressin, renin-angiotensin system response
- May play a selective role in vasoconstriction
Hepatorenal Reflex-Putative

- Amino acid infusion: hepatocyte swelling → reduction in GFR
- Response abolished by severing renal, hepatic, spinal nerves
- Activation by increased portal venous pressure, decreased sinusoidal flow

- Lang, Tschernko, Haussinger Exp Physiol 1992:77,663
HRS: Pathophysiologic Mechanisms

Cardiac dysfunction → circulatory derangements and renal hypoperfusion:

- Impaired myocardial function observed
- ↓ Myocardial beta receptor transduction
- NOx and cytokine inhibition of function
- Diastolic dysfunction
- Impaired contractility
Cytokine/mediator action on renal circulation:
- NOx greatest attention
- Splanchnic shear stress $\rightarrow$ increased eNOS $\rightarrow$ increased NOx
- Lots of evidence for increased NOx
- Shouldn’t it counteract renal vasoconstriction?
1. ↑ Renal sodium retention
2. ↓ Capacity to secrete solute free water
3. Hyponatremia
4. ↓ GFR

Atrial natriuretic peptide
Cardiac dysfunction
↓ Renal VD ↑ Renal VC

RAAS
Vasopressin release
↑ SNS
Baroreceptor activation

Portal hypertension
↑ NO
Splanchnic vasodilation
↓ Effective circulating volume

Renal VD
Renal VC
Vasopressin release

↑ RAAS

Tachycardia

Cardiac dysfunction

Renal vessels
Worsening hyperdynamic circulation
Cardiac dysfunction
(septic or cirrhotic cardiomyopathy)

Bacterial infection
Large volume paracentesis
GI Bleeding
Acute alcoholic hepatitis

Renal vasoconstriction

↑ Renal vasoconstrictor
↓ Renal vasodilator

HRS

Aggravating/Precipitating Factors
HRS: Prognosis

- Adult data
- Type 1: 80% 2 week mortality, 90% 3 month
- Type 2: 6 month median survival
- Prognosis worse if precipitating factor exists
- Severity of liver disease a determinant of survival
HRS: Treatment

- General measures:
  - Central venous access
  - Monitor fluid status
  - Volume: albumin/furosemide to titrate CVP
  - Nutrition critical: avoid high protein; low salt, free water restriction
HRS: Specific Treatments

- Renal vasodilators
- Systemic vasoconstrictors
- TIPS
- Renal replacement therapy
- Liver/renal replacement therapy
- Liver transplantation
HRS Treatment: Vasodilators

- Dopamine
- Fenoldopam
- Low-dose dopamine: no benefit for HRS GFR or urine flow
HRS Treatment: Systemic Vasoconstrictors

- Most promising pharmacologic agents
- Effort to decrease splanchnic vasodilation
  - Vasopressin analogues (terlipressin, vasopressin)
  - Somatostatin analogues (octreotide): not effective
  - Alpha-adrenergic agonists (norepinephrine)
V1 receptor agonist-arterial smooth muscle

Terlipressin best studied
- Improved GFR, reduction of creatinine in 42-77% in several studies
- In combination with albumin
- Palliative only

Vasopressin used in US due to availability

What is renal effect?
HRS Treatment: TIPS

- Transjugular intrahepatic portosystemic shunt
- Reduction of portal venous pressure → possible suppression of hepatorenal reflex, improved function
- 10 week HRS survival 53-81% with TIPS in adults
HRS Treatment: TIPS

- Response: ability to d/c dialysis
- Decreased vasoconstrictor substances
- Hepatic encephalopathy and cardiac function may worsen
- Experience with children has been primarily for portal hypertension (> 5 years)
HRS Treatment: Renal Replacement Therapy

- May be reasonable option as bridge to transplant
- CRRT better tolerated than HD (Davenport, Detry)
- Cytokine removal produced: but is it an advantage?
- Prospective study: no benefit of CRRT over HD - BUT all ventilated pts. got CRRT (Witzke, 2004)
- Benefit of high ultrafiltrate flow CVVH?
Is Plasmapheresis Alone Helpful for Hepatic Failure in Children?

- 49 children with FHF
- Daily pheresis until death or transplantation
- Improved coagulopathy
- No sustained CNS improvement
- No impact on recovery

- Singer et al., Annals of Surgery 2001
HRS Treatment: Extracorporeal Liver Support Devices

• Promising therapy
• = RRT + LRT
• 2 Basic Approaches
  • Artificial
    ◦ MARS
    ◦ Prometheus
    ◦ Coupled plasma filtration/absorption and hemofiltration
  • Non-artificial
    ◦ Hepatocyte supported
I have no financial interest to disclose regarding these devices
HRS Treatment: MARS Experience

- MARS: Molecular Adsorbent Recycling System
- Polysulfone high permeability dialyzer (< 50K MW)
- 20% albumin dialysis for protein-bound (bilirubin, etc.) toxins
- Cleansing system to recycle dialysate
  - Hemofiltration
  - Charcoal adsorbent column
  - Anion exchanger
- Hemofiltration removes water-soluble toxins (NH$_3$, creatinine), and allows fluid balance
MARS System

- MARS® FLUX DIALYZER
- diaMARS® ADSORPTION COLUMNS
- diaFLUX DIALYZER

PATIENT  BLOOD CIRCUIT  MARS® ALBUMIN CIRCUIT  DIALYSATE CIRCUIT
HRS Treatment: MARS Experience

- International MARS registry (over 176 patients, some children)
- Anecdotal reports (4 in children)
- Industry data: 79 pts., improved encephalopathy
- Prospective Adult RCTs
  - Mittzner (2000)
    - 6/8 MARS vs. 5/5 control deaths
    - Mean survival 25d vs. 4.6 days
    - Buying time?
  - Heeman (2002)
    - 1/12 MARS vs. 6/12 control deaths
Prometheus System

- Mythological foundation
- Newer artificial liver/kidney support device
- Fractionated plasma separation and adsorption (Falkenhagen, 1999)
- Possible advantages over MARS
Flow diagram of the Prometheus System

- Patient
- FPSA circuit
  - prometh®01
  - prometh®02
- AlbuFlow®
- Dialysis circuit
  - Fresenius Polysulfone® high-flux dialyzer
ELKS System Differences

- **MARS**
  - 50 kDa filter
  - Dialyzed albumin passes through adsorbers
  - Hemodialysis of dialyzed fraction only
  - Plasma/HD circuits in series

- **Prometheus**
  - 250 kDa filter
  - All separated albumin passed through adsorbers
  - High flux hemodialysis of all blood: better renal effect?
  - Plasma/HD circuits in parallel: can perform one or both
Prometheus: Clinical Experience

- Case reports:
  - Young adult-cocaine ingestion, rhabdomolysis, liver failure
  - 2 year old in liver failure for retransplant
- Small case series (N = 9,11) with good clearance of ammonia, bilirubin, creatinine
- No clinical outcome data

-Rifai, Manns, Ther Apher Dial 2006
Crossover trial: MARS vs. Prometheus:
- Prometheus-higher clearance of ammonia, urea
- Higher reduction ratios

Crossover trial for cytokine clearance
- Cytokines elevated baseline
- Both produced clearance but no overall effect on serum levels

- Stadlbauer et al., Crit Care 2006
- Evenepoel et al., Artificial Organs 2006
Current Device Use

- MARS and Prometheus used in Europe
- MARS FDA approved in adults in US for certain conditions/not approved for use in children
- No pediatric trials to date/no plans for US pediatric study at present
- Small MARS filters/lines (60 ml and 0.6 m² area) now available for children
HRS Treatment: Extracorporeal Liver Support Devices

- Meta-analysis
  - Review of 12 trials
  - Overall support systems: no mortality effect BUT revised (-1973 trial) RR 0.78; 95% CI 0.61-1.00
  - Mortality
    - reduced in acute-on-chronic liver failure (RR 0.67; 95% CI 0.51-0.90)
    - not in acute liver failure

-Kjaergard et al., JAMA 2003
HRS Treatment: Liver Transplantation

- Still the most definitive treatment for HRS
- 2 year OLT patient and graft survival similar with and without HRS (Gomwa et al., 1991)
- More recent: HRS post-transplant ARF reversal in only 58% (Marik, NDT, 2005)
- BUT similar to non-HRS patients IF treated with vasopressin pre-op (Arroyo, Hepatology, 2005)
HRS Treatment: Liver Transplantation

- Post-tx renal recovery in HRS also more likely in younger adults, non-alcoholic liver dz
- In acute FHF, getting to transplant is the problem
- HRS NOT an exclusion in AASLD transplant guidelines (but think about it!)
Conclusions

- Liver interactions potentially alter kidney function in critical illness
- Renal vasoconstriction drives HRS
- Hepatorenal syndrome is a potential risk for children with high mortality
- Multiple therapies for HRS-no magic bullet
- Potential for extracorporeal devices in adults and children
Liver and Kidney Go Well Together
Liver-Kidney Interactions
Liver Transplantation: Post-Op Impact on Renal Function

- Renal function in general worsens over time
  - Adults: 10% incidence
  - Children: post-transplant up to 32%
HRS: Diagnosis

- Clinical criteria: need major criteria to differentiate
- May be difficult to differentiate from other causes of ARF in liver failure
- Urine sodium may be helpful
- HRS may have high urine sodium if treated with diuretics
This document was created with Win2PDF available at http://www.win2pdf.com. The unregistered version of Win2PDF is for evaluation or non-commercial use only. This page will not be added after purchasing Win2PDF.